Exparel provides pain relief for up to 72 hours after administration. That’s roughly three days of local analgesia from a single injection, compared to standard bupivacaine, which typically wears off in less than 24 hours. The actual duration varies depending on the type of surgery, where the injection is placed, and individual factors like body composition and metabolism.
How Exparel Releases Over 72 Hours
Exparel is bupivacaine, the same local anesthetic used in standard nerve blocks and surgical injections, but packaged inside microscopic fat-based bubbles called multivesicular liposomes. These tiny structures act like slow-dissolving capsules. Instead of releasing all the medication at once, they break down gradually over days, keeping a steady supply of numbing agent at the surgical site.
The release happens in three distinct phases. First, a small burst of medication provides almost immediate relief. About 3% of the bupivacaine sits outside the liposomes, which is why pain relief can begin within minutes of the injection. In clinical testing, patients reported meaningful pain reduction as early as 2 minutes after administration, with significant effects at 5, 15, and 30 minutes.
After that initial burst, the drug enters a slower phase where bupivacaine gradually diffuses through the lipid membranes of the liposomes. This is followed by a secondary release phase as the liposome particles physically erode and break apart. Together, these phases stretch the pain-relieving window from hours to days.
What Pain Relief Actually Looks Like
The 72-hour window is the upper limit, not a guarantee of complete numbness for three full days. Pain relief is strongest in the first 24 to 48 hours and gradually tapers. Most people still need some form of additional pain medication during recovery, but the goal is to reduce how much and how soon.
In a study of patients undergoing knee replacement, those who received Exparel waited an average of 6.3 hours before needing their first rescue pain medication, compared to 5 hours for patients who didn’t receive it. Over the full 72-hour recovery window, the Exparel group used significantly less opioid medication: about 209 milligrams of morphine equivalents versus 248 milligrams in the control group. For hip replacement patients, the delay to first rescue medication was even longer (7.1 hours versus 4.9 hours), though overall opioid use between the two groups didn’t differ significantly.
These numbers illustrate an important point: Exparel doesn’t eliminate postoperative pain. It reduces the need for opioids and buys extra time before stronger medications become necessary. You should expect some discomfort even with Exparel on board, particularly as the medication tapers on days two and three.
Where Exparel Is Used
Exparel was first approved in 2011 for injection directly into surgical sites to manage pain after surgery. It has since been evaluated for use in peripheral nerve blocks, where the medication is injected near specific nerves to numb a larger region. The nerve blocks studied in clinical trials include the brachial plexus block (for shoulder surgeries like rotator cuff repair and total shoulder replacement), intercostal nerve blocks (for chest surgery), and femoral nerve blocks (for total knee replacement).
Your surgeon or anesthesiologist chooses between a local tissue injection and a nerve block based on the type of procedure. A nerve block tends to provide broader coverage, while a direct wound injection targets the specific area of tissue trauma. In both cases, the 72-hour release profile is the same, though the experience of pain relief can differ depending on the anatomy involved.
How It Compares to Standard Bupivacaine
Standard bupivacaine, the non-liposomal version, typically provides pain relief for less than 24 hours. In many cases, it wears off within 8 to 12 hours depending on the dose and injection site. Exparel extends that window to 48 to 72 hours, roughly tripling the duration of a single injection.
This difference matters most in the first two days after surgery, when pain tends to be worst and opioid use is highest. By covering that critical window with a local anesthetic, Exparel can reduce your reliance on oral or IV opioids during the period when side effects like nausea, sedation, and constipation are most disruptive to recovery.
Safety Considerations
Because Exparel releases bupivacaine slowly into surrounding tissue, it carries the same risks as any local anesthetic, including a rare but serious complication called local anesthetic systemic toxicity. This occurs when too much of the drug enters the bloodstream, potentially causing seizures or cardiac problems. The risk is highest if the medication is accidentally injected into a blood vessel rather than the intended tissue.
The maximum recommended dose is 266 mg (one 20 mL vial of undiluted product) for adults. For children aged 6 and older, the dose is weight-based at 4 mg per kilogram, capped at the same 266 mg maximum. Your surgical team calculates the appropriate dose before administration, and monitoring during and after the injection is standard practice.
One practical detail worth knowing: Exparel should not be mixed with other local anesthetics in the same syringe. If your anesthesiologist uses standard bupivacaine alongside Exparel (for example, to speed up the onset of a nerve block), the two are administered separately with at least 20 minutes between injections to avoid disrupting the liposome structure.